RESUMEN
Platelet suspensions, that secreted about 50% of their dense granule contents upon stimulation with alpha-thrombin, showed a dose-dependent increase in secretion after 30 min preincubation with 0.5-3.0 g low density lipoprotein (LDL) protein/1. A 1-5 min preincubation had no effect. The enhancement by LDL only occurred at about 20% secretion or more, indicating that a minimal degree of activation was required for LDL to become effective. Lysine-modified LDL was equally effective as native LDL. The effect of LDL on secretion was accompanied by enhanced thromboxane B2 formation caused by stimulation of the liberation of arachidonate from phosphatidylcholine and/or phosphatidylinositol. However, when thromboxane formation was inhibited or the prostaglandin H2-thromboxane A2-receptor was blocked, LDL remained a potent stimulator of the secretion response. Thus, LDL enhances platelet secretion by a thromboxane A2-dependent and a thromboxane A2-independent mechanism via an effect that is independent of specific binding sites on the platelet.
Asunto(s)
Plaquetas/fisiología , Lipoproteínas LDL/fisiología , Activación Plaquetaria , Ácidos Araquidónicos/metabolismo , Humanos , Cinética , Trombina/fisiología , Tromboxano B2/metabolismoRESUMEN
Although platelets have specific bindingsites for LDL and HDL, it is doubtful whether lipoproteins modulate platelet functions via receptor-mediated processes. We investigated platelet-lipoprotein interaction during prolonged incubation with concentrations of LDL and HDL that saturate the bindingsites within a few minutes. When [3H]arachidonate-labeled human platelets were incubated for 4 h with lipoproteins, part of the 3H-radioactivity transferred to LDL and to a lesser extent to HDL. The transfer was temperature-sensitive, unaffected by modification of lysine in LDL or indomethacin treatment of the platelets, and almost irreversible. [3H]arachidonate transfer to lipoproteins could be mimicked by incubating platelets with a high concentration of fatty acid free albumin. This showed, that the loss of 3H-radioactivity reflected a decrease in endogenous arachidonate, leading to impaired aggregation, secretion and thromboxane B2 formation in platelets after stimulation with thrombin but not with arachidonate. Thus, the decrease in platelet functions seen after long incubation with HDL is caused by depletion of platelet arachidonate. Despite an even stronger arachidonate depletion by LDL, this lipoprotein initiated arachidonate metabolism and secretion independent of specific binding sites for LDL on the platelet. Surprisingly, the major part of the secretion was preserved when the formation of prostaglandin endoperoxides/thromboxane A2 was inhibited with indomethacin. These findings argue against a role for LDL and HDL receptors in the modulation of platelet functions and are more in favor of lipid exchange processes between platelets and lipoproteins.
Asunto(s)
Ácido Araquidónico/sangre , Plaquetas/metabolismo , Lipoproteínas HDL/sangre , Lipoproteínas LDL/sangre , Adenosina Trifosfato/metabolismo , Humanos , Agregación Plaquetaria/efectos de los fármacos , Serotonina/metabolismo , Albúmina Sérica/metabolismo , Tromboxano B2/biosíntesisRESUMEN
Studies with isolated lipoproteins and washed platelets suggest that lipoproteins may affect platelet functions. We investigated platelet-rich plasma (PRP) from a patient with abetalipoproteinemia (ABL), whose plasma lacks apo-B containing lipoproteins (VLDL, LDL and chylomicrons). ABL-PRP aggregated poorly with different agonists and failed to respond to arachidonate. Thromboxane B2 (TxB2) formation was severely impaired. After gel-filtration most of the aggregation defects persisted in agreement with reduced metabolism of endogenous arachidonate. However, arachidonate-induced aggregation and TxB2 production partially normalized. Normal platelets suspended in ABL-plasma showed similar defects in aggregation and TxB2 production but arachidonate-induced aggregation was much lower than expected on the basis of TxB2. We conclude that the abnormal platelet functions in ABL-PRP are caused by (i) an intrinsic platelet abnormality due to reduced arachidonate mobilization and (ii) a property in ABL plasma that inhibits aggregation partially by trapping the arachidonate and partially by an unidentified mechanism. The latter properties may be the result of the abnormal lipid composition of ABL-plasma.
Asunto(s)
Abetalipoproteinemia/sangre , Plaquetas/fisiología , Adenosina Trifosfato/metabolismo , Adulto , Ácido Araquidónico , Ácidos Araquidónicos/sangre , Plaquetas/metabolismo , Femenino , Citometría de Flujo , Humanos , Agregación Plaquetaria/fisiologíaRESUMEN
The degradation of platelet-activating factor (PAF) in plasma is catalyzed by PAF-acetylhydrolase resulting in lyso-PAF which is biologically inactive. Normally, most of the PAF-degrading activity is associated with low-density lipoproteins (LDL). The enzyme activity was measured in the plasma of a patient with abetalipoproteinemia, a disorder characterized by the absence of apolipoprotein-B-containing lipoproteins (chylomicrons, VLDL and LDL). Here we report that the plasma of the patient has a normal activity of PAF-acetylhydrolase. The enzyme activity is bound to high-density lipoproteins (HDL) and shows the kinetic properties of the LDL-associated enzyme of healthy subjects. Following administration of artificial triglyceride-rich particles (ATRP), part of the enzyme activity is found associated with ATRP, indicating that PAF-acetylhydrolase can transfer from HDL to triglyceride-containing lipid complexes in vivo.